Trial
NCT02134717
Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes
UnknownTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Kevin F. Gibson
Collaborators
University of Pittsburgh
Condition
Sarcoidosis
Intervention
all subjects will receive maraviroc 300mg orally twice a day for 6 weeks
Why stopped
Poor recruitment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-03